ESMO Preceptorship on Colorectal Cancer Multidisciplinary management, standards of care and future perspectives March 27-28th 2015, SINGAPORE Co-Chairs: Jean-Yves Douillard, France Claus-Henning Köhne, Germany LEARNING OBJECTIVES  To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings  To understand the importance of pathology and histoprognostic factors  To learn about the management of patients after progression, side-effects of treatments, and in special situations Friday, 27th March 2015 09:00-9:15 Welcome and introduction 09:15 ‐10:50 Session 1 95’ Early colorectal cancer 30‘ The point of view of the pathologist - Quality and rules of a good pathology report - Histoprognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression 20’ State‐of‐the‐art: Standard of surgical practice for resectable colo‐rectal cancer (special issues on rectal cancer) 30’ State‐of‐the‐art: Standard(s) of perioperative radio/chemotherapy for rectal cancer 15’ Discussion 10:50-11:10 Coffee Break 11:10-13:00 Session 2 105‘ Adjuvant settings of colorectal cancer 30‘ Microsatellite instability: Where do we stand? How useful is it? 30‘ Adjuvant treatment for colon cancer III Page 1 of 3 esmo.org 30‘ Adjuvant treatment of stage II Which patients to treat? 20‘ Discussion 13:00-14:00 LUNCH 60‘ 14:00-14:30 Session 3 30’ Clinical cases 30‘ 2 Clinical cases from participants (10‘/case + 5’discussion) 14:30-16:15 Session 4: Metastatic colorectal cancer, liver limited metastases 105‘ 15‘ Review of the ESMO consensus conference on metastatic colorectal cancer - Basic strategies and groups (RASwt /mut, BRAF mut) 15’ Development of conventional chemotherapy in mCRC, BSC vs, Chemo, biochemical modulation, oral fluoropyrimidines, development of combination chemotherapy 30‘ Resection of liver limited metastasis (Resectable cases, Group 0) - Upfront - After neo-adjuvant treatment - Repeated hepatectomy 30‘ Unresectable or borderline resectable (Group 1) chemotherapy +/- targetd agents 15‘ Discussion 16:15-16:45 Coffee Break 16:45-18:30 Session 5 105‘ Special clinical situations: Mono- or oligometastatic disease 30‘ Treatment of metastatic disease confined to the peritoneum - Resection - HIPEC - PIPEC 30‘ Options of locoregional treatment of liver metastasis - intraarterial therapy - chemoembolisation - SIRT - Local radiation 30‘ Primary with synchroneous metastases 15‘ Discussion Page 2 of 3 esmo.org Time TBC Dinner Saturday, 28 May 2014 09:00-10:30 Session 6 90‘ Metastatic colorectal cancer I 25‘ The role of EGFR inhibition in mCRC 25‘ The role of VEGF inhibition in mCRC 10‘ Discussion 25‘ The role of maintenance, appropriate endpoints according to ESMO consensus 5‘ Discussion 10:30-11:00 Coffee Break 11:00-12:15 Session 7 75‘ Metastatic colorectal cancer II 30‘ - The Continuum of Care in colorectal cancer versus lines of treatment - Appropriate use of new agents (aflibercept and regorafenib) within the treatment algorithm - Re-introduction of regimens? 30‘ Management of treatment related side effects - GI-Toxicity - Neuropathy - Skin toxicity - Hypertension Hand-foot syndrome 15‘ Discussion 12:15-13:00 Session 8 45‘ Case presentations from participants followed by panel discussion 3X15‘ 3 Clinical cases from participants (10‘/case + 5’discussion) 13:00-13:15 Conclusion and farewell 15‘ 13:15-14:00 LUNCH Page 3 of 3 esmo.org